This PhD is funded by Cancer Research UK and includes bench fees, tuition fees and a living stipend ~£19,000 pa.
N.B. Fees are only funded to Home/EU rate so international; applications must be able self-fund the difference.
Gogola E, Rottenberg S, Jonkers J. Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer. Annual Review of Cancer Biology. 2019; 3:235-254
Higgs MR, Sato K, Reynolds JJ, Begum S, Bayley R, Goula A, Vernet A, Paquin KL, Skalnik DG, Kobayashi W, Takata M, Howlett NG, Kurumizaka H, Kimura H, Stewart GS. Histone Methylation by SETD1A Protects Nascent DNA through the Nucleosome Chaperone Activity of FANCD2. Mol Cell. 2018; 71(1):25-41.
Begum S, Goula A, Bayley R, Higgs MR. On your marks, get SET(D1A): the race to protect stalled replication forks. Mol Cell Oncol. 2018; 5(6):e1511209.
Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010; 116(22):4578-87.